Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Jinbing Zhu, Qiuji Wu, Jinjin Wang & Ting Niu. (2022) Cost-effectiveness analysis of azacitidine maintenance therapy in patients with acute myeloid leukemia. Expert Review of Hematology 15:4, pages 375-382.
Read now
Read now
Crystal Watson, Arie Barlev, Jodie Worrall, Steve Duff & Rachel Beckerman. (2021) Exploring the burden of short-term CHOP chemotherapy adverse events in post-transplant lymphoproliferative disease: a comprehensive literature review in lymphoma patients. Journal of Drug Assessment 10:1, pages 18-26.
Read now
Read now
Ivo Abraham, Uchenna Onyekwere, Baris Deniz, Donald Moran, Marc Chioda, Karen MacDonald & Huan Huang. (2021) Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy. Journal of Medical Economics 24:sup1, pages 71-83.
Read now
Read now
John Edelsberg, Derek Weycker, Mark Bensink, Charles Bowers & Gary H. Lyman. (2020) Prophylaxis of febrile neutropenia with colony-stimulating factors: the first 25 years. Current Medical Research and Opinion 36:3, pages 483-495.
Read now
Read now
Antroula Papakonstantinou, Elham Hedayati, Mats Hellström, Hemming Johansson, Michael Gnant, Günther Steger, Richard Greil, Michael Untch, Volker Moebus, Sibylle Loibl, Theodoros Foukakis, Jonas Bergh & Alexios Matikas. (2020) Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer. Acta Oncologica 59:1, pages 75-81.
Read now
Read now
R. Andrew Harkins, Sharvil P. Patel & Christopher R. Flowers. (2019) Cost burden of diffuse large B-cell lymphoma. Expert Review of Pharmacoeconomics & Outcomes Research 19:6, pages 645-661.
Read now
Read now
Kelly Fust, Anju Parthan, Michael Maschio, Qing Gu, Xiaoyan Li, Gary H. Lyman, Spiros Tzivelekis, Guillermo Villa & Milton C. Weinstein. (2017) Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models. Expert Review of Pharmacoeconomics & Outcomes Research 17:1, pages 39-52.
Read now
Read now
Articles from other publishers (17)
Matti S. Aapro, Stephen Chaplin, Paul Cornes, Sebastian Howe, Hartmut Link, Natalia Koptelova, Andrea Mehl, Mario Di Palma, Bridgette Kanz Schroader & Robert Terkola. (2023) Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer. Supportive Care in Cancer 31:10.
Crossref
Crossref
Moonho Kim, Yongchel Ahn, Heui-June Ahn, Suk-Hun Ha, Ho-Suk Oh, Jae-Seok Song, Woong-Sub Park & Sang-Wook Yi. (2023) Impact of primary prophylaxis by pegfilgrastim in diffuse large B-cell lymphoma treated with R-CHOP. Annals of Hematology.
Crossref
Crossref
Shu-Wei Hsu, Shao-Chin Chiang, Jason C. Hsu & Yu Ko. (2023) Prescription patterns of granulocyte colony–stimulating factors in patients with breast cancer: A real-world study. PLOS ONE 18:7, pages e0288642.
Crossref
Crossref
Girma Tekle Gebremariam, Atalay Mulu Fentie, Kebede Beyene, Beate Sander & Gebremedhin Beedemariam Gebretekle. (2022) Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review. BMC Health Services Research 22:1.
Crossref
Crossref
Seong Hyun Jeong, Seok Jin Kim, Dok Hyun Yoon, Yong Park, Hye Jin Kang, Youngil Koh, Gyeong-Won Lee, Won-Sik Lee, Deok-Hwan Yang, Young Rok Do, Min Kyoung Kim, Kwai Han Yoo, Yoon Seok Choi, Hwan Jung Yun, Jun Ho Yi, Jae-Cheol Jo, Hyeon-Seok Eom, Jae-Yong Kwak, Ho-Jin Shin, Byeong Bae Park, Shin Young Hyun, Seong Yoon Yi, Ji-Hyun Kwon, Sung Yong Oh, Hyo Jung Kim, Byeong Seok Sohn, Jong Ho Won, Se-Hyung Kim, Ho-Sup Lee, Cheolwon Suh & Won Seog Kim. (2022) Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study. Cancer Research and Treatment 54:4, pages 1268-1277.
Crossref
Crossref
Yu Kondo, Tomoya Tachi, Takayoshi Sakakibara, Jun Kato, Aki Kato, Takahito Mizuno, Yoshio Miyake & Hitomi Teramachi. (2022) Cost-effectiveness analysis of pegfilgrastim in patients with non-small cell lung cancer receiving ramucirumab plus docetaxel in Japan. Supportive Care in Cancer 30:8, pages 6775-6783.
Crossref
Crossref
Paul Cornes, John Kelton, Rongzhe Liu, Omer Zaidi, Jennifer Stephens & Jingyan Yang. (2022) Real-world cost–effectiveness of primary prophylaxis with G-CSF biosimilars in patients at intermediate/high risk of febrile neutropenia. Future Oncology 18:16.
Crossref
Crossref
Qiuji Wu, Yi Qin, Weiting Liao, Mengxi Zhang, Yang Yang, Pengfei Zhang & Qiu Li. (2022) Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma. Therapeutic Advances in Medical Oncology 14, pages 175883592110687.
Crossref
Crossref
Qiuji Wu, Qiu Li, Jun Zhang, Zhumei Luo, Jin Zhou, Jing Chen & Yong Luo. (2021) Comparison of Primary and Secondary Prophylaxis Using PEGylated Recombinant Human Granulocyte–Stimulating Factor as a Cost-Effective Measure in Malignant Neoplasms: A Multicenter Retrospective Study. Frontiers in Pharmacology 12.
Crossref
Crossref
Edward Li, Dylan J. Mezzio, David Campbell, Kim Campbell & Gary H. Lyman. (2021) Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness Analysis. JCO Oncology Practice 17:8, pages e1235-e1245.
Crossref
Crossref
Darren M.C. Poon, Kuen Chan, Tim‐Wai Chan, Bryan Ng, Steven Siu, Joyce Ng, David Johnson & Ka Chai Lee. (2021) Prevention of docetaxel‐associated febrile neutropenia with primary granulocyte colony‐stimulating factor in Chinese metastatic hormone‐sensitive and castration‐resistant prostate cancer patients. Asia-Pacific Journal of Clinical Oncology 17:S3, pages 39-47.
Crossref
Crossref
Paul Cornes & Andriy Krendyukov. (2019) The evolution of value with filgrastim in oncology. Future Oncology 15:13, pages 1525-1533.
Crossref
Crossref
Ulrikke J. V. Hernæs, Kjell A. Johansson, Trygve Ottersen & Ole F. Norheim. (2017) Distribution-Weighted Cost-Effectiveness Analysis Using Lifetime Health Loss. PharmacoEconomics 35:9, pages 965-974.
Crossref
Crossref
Kelly Fust, Xiaoyan Li, Michael Maschio, Guillermo Villa, Anju Parthan, Richard Barron, Milton C. Weinstein, Luc Somers, Caroline Hoefkens & Gary H. Lyman. (2016) Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma. PharmacoEconomics 35:4, pages 425-438.
Crossref
Crossref
Xiao Jun Wang, Tiffany Tang, Mohamad Farid, Richard Quek, Miriam Tao, Soon Thye Lim, Hwee Lin Wee & Alexandre Chan. (2016) Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy. PLOS ONE 11:2, pages e0148901.
Crossref
Crossref
Valentina Bozzoli, Maria C. Tisi, Elena Maiolo, Eleonora Alma, Silvia Bellesi, Francesco D'Alo’, Maria T. Voso, Giuseppe Leone & Stefan Hohaus. (2015)
Four doses of unpegylated
versus
one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma
. British Journal of Haematology 169:6, pages 787-794.
Crossref
Crossref
Esther K. Lee, William W. L. Wong, Maureen E. Trudeau & Kelvin K. W. Chan. (2015) Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D. Breast Cancer Research and Treatment 150:1, pages 169-180.
Crossref
Crossref